Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 6/20 | 0.33 |
| ▸ | CA2 | P00918 | 6/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13924851 | 1.00 | TAAR1 (0.41) | TAAR1HTR2ACA1CA2LMNA | |
| SCHEMBL3963217 | 1.00 | TAAR1 (0.41) | TAAR1HTR2ACA1CA2LMNA | |
| SCHEMBL2761717 | 0.98 | TAAR1 (0.42) | TAAR1HTR2ACA1CA2IDO1 | |
| SCHEMBL9340660 | 0.92 | TAAR1 (0.43) | TAAR1HTR2AIDO1NPC1HPGD | |
| SCHEMBL3396819 | 0.81 | CA1 (0.39) | TAAR1CA1CA2 | |
| SCHEMBL18421431 | 0.81 | CA2 (0.33) | CA1CA2 | |
| SCHEMBL30891617 | 0.81 | GFER (0.46) | TAAR1CA1CA2 | |
| SCHEMBL12727813 | 0.81 | CYP1A2 (0.41) | TAAR1CA1CA2IDO1NPC1 | |
| SCHEMBL3426890 | 0.81 | CA2 (0.35) | CA1CA2 | |
| SCHEMBL12971204 | 0.81 | CA1 (0.33) | CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3638643-B1 | PROCESS FOR THE PREPARATION OF SEMIFLUORINATED ALKANES USING GRIGNARD REAGENTS | NOVALIQ GMBH (DE) | 2023-01-18 | — | — | EP | disclosed |
| US-20200339492-A1 | PROCESS FOR THE PREPARATION OF SEMIFLUORINATED ALKANES USING GRIGNARD REAGENTS | NOVALIQ GMBH (DE) | 2020-10-29 | — | — | US | disclosed |
| EP-3638643-A1 | PROCESS FOR THE PREPARATION OF SEMIFLUORINATED ALKANES USING GRIGNARD REAGENTS | Novaliq GmbH (DE) | 2020-04-22 | — | — | EP | disclosed |
| WO-2018228975-A1 | PROCESS FOR THE PREPARATION OF SEMIFLUORINATED ALKANES USING GRIGNARD REAGENTS | NOVALIQ GMBH (DE) | 2018-12-20 | — | — | WO | disclosed |
| US-6727390-B2 | INCREASING FLUOROUS NATURE OF A COMPOUND BY REACTING THE COMPOUND WITH OR TAGGING THE COMPOUND WITH FLUOROUS PHOSPHINES AND PHOSPHINE OXIDES | UNIVERSITY OF PITTSBURGH | 2004-04-27 | — | — | US | disclosed |
| US-20020183521-A1 | Fluorous phosphines and phosphine oxides | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-12-05 | — | — | US | disclosed |
| WO-2002081486-A1 | FLUOROUS PHOSPHINES AND PHOSPHINE OXIDES | UNIVERSITY OF PITTSBURGH (US) | 2002-10-17 | — | — | WO | disclosed |
| EP-0959987-B1 | USE OF PERFLUOROALKYL SUBSTITUTED PHOSPHORUS COMPOUNDS AS LIGANDS FOR HOMOGENEOUS CATALYSIS IN SUPERCRITICAL CARBON DIOXIDE | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 2001-08-08 | — | — | EP | disclosed |
| EP-0959987-A1 | USE OF PERFLUOROALKYL SUBSTITUTED PHOSPHORUS COMPOUNDS AS LIGANDS FOR HOMOGENEOUS CATALYSIS IN SUPERCRITICAL CARBON DIOXIDE | Studiengesellschaft Kohle mbH (DE) | 1999-12-01 | — | — | EP | disclosed |
| WO-1998032533-A1 | USE OF PERFLUOROALKYL SUBSTITUTED PHOSPHORUS COMPOUNDS AS LIGANDS FOR HOMOGENEOUS CATALYSIS IN SUPERCRITICAL CARBON DIOXIDE | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 1998-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183521-A1 | Fluorous phosphines and phosphine oxides | PFAS, AFF1, AFF2 | TAAR1 158/4885HTR2A 4043/4885CA1 3259/4885 |
| US-20200339492-A1 | PROCESS FOR THE PREPARATION OF SEMIFLUORINATED ALKANES USING GRIGNARD REAGENTS | FLI1, AFF2, GTF2I | TAAR1 1176/4885HTR2A 3796/4885CA1 2461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.